Allosteric inhibition of human factor XIa: Discovery of monosulfated benzofurans as a class of promising inhibitors

Journal of Medicinal Chemistry

Volumn 57, Issue 8, 2014, Pages 3559-3569

  Argade, Malaika D ^a   Mehta, Akul Y ^a   Sarkar, Aurijit ^a   Desai, Umesh R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOFURAN DERIVATIVE; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING INHIBITOR; HEPARIN;

ALLOSTERISM; ARTICLE; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG MECHANISM; DRUG SCREENING; DRUG SULFATION; DRUG SYNTHESIS; FLUORESCENCE SPECTROSCOPY; MICHAELIS MENTEN KINETICS; MOLECULAR DOCKING; MOLECULAR MODEL; PHOTOCHEMICAL QUENCHING; PREDICTION; PROTEIN DOMAIN; WILD TYPE;

ALLOSTERIC SITE; ANTICOAGULANTS; BENZOFURANS; BINDING SITES; DRUG DISCOVERY; FACTOR XIA; HUMANS; MOLECULAR DOCKING SIMULATION;

EID: 84899534776     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5002698     Document Type: Article

References (53)

1. Cove, C. L.; Hylek, E. M. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes J. Am. Heart Assoc. 2013, 2, e000136
2. Henry, B. L.; Desai, U. R. Anticoagulants. In Burger's Medicinal Chemistry, Drug Discovery and Development, 7 th ed.; Rotella, D.; Abraham, D. J., Eds.; John Wiley and Sons: New York, 2010; pp 365-408.
3. Liew, A.; Eikelboom, J. W.; O'Donnell, M.; Hart, R. G. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants Can. J. Cardiol. 2013, 29, S34-44
4. Simonsen, C. Z.; Steiner, T.; Tietze, A.; Damgaard, D. Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion J. Stroke Cerebrovasc. Dis. 2014, 23, e133-134
5. Pfeilschifter, W.; Luger, S.; Brunkhorst, R.; Lindhoff-Last, E.; Foerch, C. The gap between trial data and clinical practice-An analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation Cerebrovasc. Dis. 2013, 36, 115-119
6. Villa, L. A.; Malone, D. C.; Ross, D. Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis Int. J. Hematol. 2013, 98, 390-397
7. Cossette, B.; Pelletier, M. E.; Carrier, N.; Turgeon, M.; Leclair, C.; Charron, P.; Echenberg, D.; Fayad, T.; Farand, P. Evaluation of bleeding risk in patients exposed to therapeutic unfractionated or low-molecular-weight heparin: a cohort study in the context of a quality improvement initiative Ann. Pharmacother. 2010, 44, 994-1002
8. Schumacher, W. A.; Luettgen, J. M.; Quan, M. L.; Seiffert, D. A. Inhibition of factor XIa as a new approach to anticoagulation Arterioscler., Thromb., Vasc. Biol. 2010, 30, 388-392
9. Wu, W.; Sinha, D.; Shikov, S.; Yip, C. K.; Walz, T.; Billings, P. C.; Lear, J. D.; Walsh, P. N. Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa J. Biol. Chem. 2008, 283, 18655-18664
10. Emsley, J.; McEwan, P. A.; Gailani, D. Structure and function of factor XI Blood 2010, 115, 2569-2577
11. Geng, Y.; Verhamme, I. M.; Smith, S. B.; Sun, M. F.; Matafonov, A.; Cheng, Q.; Smith, S. A.; Morrissey, J. H.; Gailani, D. The dimeric structure of factor XI and zymogen activation Blood 2013, 121, 3962-3969
12. Baglia, F. A.; Walsh, P. N. Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa J. Biol. Chem. 2000, 275, 20514-20519
13. Von dem Borne, P. A.; Bajzar, L.; Meijers, J. C.; Nesheim, M. E.; Bouma, B. N. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis J. Clin. Invest. 1997, 99, 2323-2327
14. Renne, T.; Oschatz, C.; Seifert, S.; Muller, F.; Antovic, J.; Karlman, M.; Benz, P. M. Factor XI deficiency in animal models J. Thromb. Haemost. 2009, 7 (Suppl 1) 79-83
15. Gailani, D.; Lasky, N. M.; Broze, G. J., Jr. A murine model of factor XI deficiency Blood Coagulation Fibrinolysis 1997, 8, 134-144
16. Yamashita, A.; Nishihira, K.; Kitazawa, T.; Yoshihashi, K.; Soeda, T.; Esaki, K.; Imamura, T.; Hattori, K.; Asada, Y. Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery J. Thromb. Haemost. 2006, 4, 1496-1501
17. Seligsohn, U. Factor XI deficiency in humans J. Thromb. Haemost. 2009, 7 (Suppl 1) 84-87
18. Gomez, K.; Bolton-Maggs, P. Factor XI deficiency Haemophilia 2008, 14, 1183-1189
19. Asakai, R.; Chung, D. W.; Davie, E. W.; Seligsohn, U. Factor XI deficiency in Ashkenazi jews in Israel N. Engl. J. Med. 1991, 325, 153-158
20. Duga, S.; Salomon, O. Factor XI deficiency Semin. Thromb. Hemost. 2009, 35, 416-425
21. Al-Horani, R. A.; Ponnusamy, P.; Mehta, A. Y.; Gailani, D.; Desai, U. R. Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa J. Med. Chem. 2013, 56, 867-878
22. Karuturi, R.; Al-Horani, R. A.; Mehta, S. C.; Gailani, D.; Desai, U. R. Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site J. Med. Chem. 2013, 56, 2415-2428
23. Sinha, D.; Badellino, K. O.; Marcinkiewicz, M.; Walsh, P. N. Allosteric modification of factor XIa functional activity upon binding to polyanions Biochemistry 2004, 43, 7593-7600
24. Gunnarsson, G. T.; Desai, U. R. Designing small, nonsugar activators of antithrombin using hydropathic interaction analyses J. Med. Chem. 2002, 45, 1233-1243
25. Gunnarsson, G. T.; Desai, U. R. Exploring new non-sugar sulfated molecules as activators of antithrombin Bioorg. Med. Chem. Lett. 2003, 13, 679-683
26. Raghuraman, A.; Riaz, M.; Hindle, M.; Desai, U. R. Rapid and efficient microwave-assisted synthesis of highly sulfated organic scaffolds Tetrahedron Lett. 2007, 48, 6754-6758
27. Raman, K.; Karuturi, R.; Swarup, V. P.; Desai, U. R.; Kuberan, B. Discovery of novel sulfonated small molecules that inhibit vascular tube formation Bioorg. Med. Chem. Lett. 2012, 22, 4467-4470
28. Raghuraman, A.; Liang, A.; Krishnasamy, C.; Lauck, T.; Gunnarsson, G. T.; Desai, U. R. On designing non-saccharide, allosteric activators of antithrombin Eur. J. Med. Chem. 2009, 44, 2626-2631
29. Al-Horani, R. A.; Liang, A.; Desai, U. R. Designing nonsaccharide, allosteric activators of antithrombin for accelerated inhibition of factor Xa J. Med. Chem. 2011, 54, 6125-6138
30. Verghese, J.; Liang, A.; Sidhu, P. P.; Hindle, M.; Zhou, Q.; Desai, U. R. First steps in the direction of synthetic, allosteric, direct inhibitors of thrombin and factor Xa Bioorg. Med. Chem. Lett. 2009, 19, 4126-4129
31. Sidhu, P. S.; Liang, A.; Mehta, A. Y.; Abdel Aziz, M. H.; Zhou, Q.; Desai, U. R. Rational design of potent, small, synthetic allosteric inhibitors of thrombin J. Med. Chem. 2011, 54, 5522-5531
32. Sidhu, P. S.; Abdel Aziz, M. H.; Sarkar, A.; Mehta, A. Y.; Zhou, Q.; Desai, U. R. Designing allosteric regulators of thrombin. Exosite 2 features multiple subsites that can be targeted by sulfated small molecules for inducing inhibition J. Med. Chem. 2013, 56, 5059-5070
33. Sidhu, P. S.; Mosier, P. D.; Zhou, Q.; Desai, U. R. On scaffold hopping: challenges in the discovery of sulfated small molecules as mimetics of glycosaminoglycans Bioorg. Med. Chem. Lett. 2013, 23, 355-359
34. Whelihan, M. F.; Orfeo, T.; Gissel, M. T.; Mann, K. G. Coagulation procofactor activation by factor XIa J. Thromb. Hemost. 2010, 8, 1532-1539
35. Lakowicz, J. R. Quenching of Fluorescence. In Principles of Fluorescence Spectroscopy, 3 rd ed.; Springer: New York, 2006, pp 278-330.
36. Yang, L.; Sun, M. F.; Gailani, D.; Rezaie, A. R. Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor Biochemistry 2009, 48, 1517-1524
37. Zhao, M.; Abdel-Razek, T.; Sun, M. F.; Gailani, D. Characterization of a heparin binding site on the heavy chain of factor XI J. Biol. Chem. 1998, 273, 31153-31159
38. Ho, D. H.; Badellino, K.; Baglia, F. A.; Walsh, P. N. A binding site for heparin in the apple 3 domain of factor XI J. Biol. Chem. 1998, 273, 16382-16390
39. Badellino, K. O.; Walsh, P. N. Localization of a heparin binding site in the catalytic domain of factor XIa Biochemistry 2001, 40, 7569-7580
40. Abdel Aziz, M. H.; Sidhu, P. S.; Liang, A.; Kim, J. Y.; Mosier, P. D.; Zhou, Q.; Farrell, D. H.; Desai, U. R. Designing allosteric regulators of thrombin. Monosulfated benzofuran dimers selectively interact with Arg173 of exosite 2 to induce inhibition J. Med. Chem. 2012, 55, 6888-6897
41. Papagrigoriou, E.; McEwan, P. A.; Walsh, P. N.; Emsley, J. Crystal structure of the factor XI zymogen reveals a pathway for transactivation Nat. Struct. Mol. Biol. 2006, 13, 557-558
42. Lin, J.; Deng, H.; Jin, L.; Pandey, P.; Quinn, J.; Cantin, S.; Rynkiewicz, M. J.; Gorga, J. C.; Bibbins, F.; Celatka, C. A.; Nagafuji, P.; Bannister, T. D.; Meyers, H. V.; Babine, R. E.; Hayward, N. J.; Weaver, D.; Benjamin, H.; Stassen, F.; Abdel-Meguid, S. S.; Strickler, J. E. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants J. Med. Chem. 2006, 49, 7781-7791
43. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748
44. Raghuraman, A.; Mosier, P. D.; Desai, U. R. Finding a needle in a haystack. Development of a combinatorial virtual screening approach for identifying high specificity heparin/heparan sulfate sequence(s) J. Med. Chem. 2006, 49, 3553-3562
45. Hu, X.; Balaz, S.; Shelver, W. H. A practical approach to docking of zinc metalloproteinase inhibitors J. Mol. Graphics Modelling 2004, 22, 293-307
46. Gohlke, H.; Hendlich, M.; Klebe, G. Knowledge-based scoring function to predict protein-ligand interactions J. Mol. Biol. 2000, 295, 337-356
47. Henry, B. L.; Monien, B. H.; Bock, P. E.; Desai, U. R. A novel allosteric pathway of thrombin inhibition. Exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids J. Biol. Chem. 2007, 282, 31891-31899
48. Szilagyi, A.; Nussinov, R.; Csermely, P. Allo-network drugs: extension of the allosteric drug concept to protein- protein interaction and signaling networks Curr. Top. Med. Chem. 2013, 13, 64-77
49. Thompson, A. D.; Dugan, A.; Gestwicki, J. E.; Mapp, A. K. Fine-tuning multiprotein complexes using small molecules ACS Chem. Biol. 2012, 7, 1311-1320
50. Hedstrom, L. Serine protease mechanism and specificity Chem. Rev. 2002, 102, 4501-4524
51. Geng, Y.; Verhamme, I. M.; Messer, A.; Sun, M. F.; Smith, S. B.; Bajaj, S. P.; Gailani, D. A sequential mechanism for exosite-mediated factor IX activation by factor XIa J. Biol. Chem. 2012, 287, 38200-38209
52. Geng, Y.; Verhamme, I. M.; Sun, M. F.; Bajaj, S. P.; Emsley, J.; Gailani, D. Analysis of the factor XI variant Arg184Gly suggests a structural basis for factor IX binding to factor XIa J. Thromb. Haemost. 2013, 11, 1374-1384
53. Samuel, D.; Cheng, H.; Riley, P. W.; Canutescu, A. A.; Nagaswami, C.; Weisel, J. W.; Bu, Z.; Walsh, P. N.; Roder, H. Solution structure of the A4 domain of factor XI sheds light on the mechanism of zymogen activation Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 15693-15698